Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1

Terminated

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Biological: Tisagenlecleucel
Drug: Ibrutinib

First Posted Date: 2019-03-15

Last Posted Date: 2023-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT03876028

Locations: 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Asciminib

First Posted Date: 2019-03-14

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT03874858

Locations: 🇮🇹
Novartis Investigative Site, Novara, Italy

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Phase 3

Completed

Conditions: Migraine

Interventions: Other: Placebo
Biological: Erenumab

First Posted Date: 2019-03-07

Last Posted Date: 2025-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 557

Registration Number: NCT03867201

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Phase 3

Completed

Conditions: Homozygous Familial Hypercholesterolemia

Interventions: Drug: Inclisiran Sodium for injection
Drug: Placebo
Drug: Placebos

First Posted Date: 2019-02-22

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03851705

Locations: 🇷🇺
(50007-001) Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
🇷🇸
(50381-001) Clinical Center of Serbia, Belgrad, Serbia
🇹🇷
(50090-001) Ege Universitesi, İzmir, Turkey

and more 10 locations

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Combination Product: Docetaxel / Capecitabine
Drug: Letrozole OR Anastrozole
Combination Product: Capecitabine / Vinorelbine
Combination Product: Paclitaxel / Gemcitabine
Drug: Goserelin

First Posted Date: 2019-02-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT03839823

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Phase 2

Completed

Conditions: Glomerulonephritis

Interventions: Drug: LNP023

First Posted Date: 2019-02-06

Last Posted Date: 2024-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT03832114

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Phase 4

Completed

Conditions: Migraine

Interventions: Biological: Erenumab
Drug: Topiramate
Drug: Topiramate matching placebo
Biological: Erenumab matching placebo

First Posted Date: 2019-02-04

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 777

Registration Number: NCT03828539

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: LYS006
Drug: Placebo to LYS006
Drug: Placebo to MAS825
Drug: Placebo to CFZ533
Drug: LOU064 25mg
Drug: LOU064 100mg
Drug: Placebo to VAY736
Drug: VAY736
Drug: Placebo to LOU064
Drug: CFZ533
Drug: MAS825

First Posted Date: 2019-02-01

Last Posted Date: 2025-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 248

Registration Number: NCT03827798

Locations: 🇺🇸
Olympian Clinical Research ., Clearwater, Florida, United States
🇺🇸
Park Avenue Dermatology, PA, Orange Park, Florida, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 6 locations

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Anastrozole
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2019-01-30

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 376

Registration Number: NCT03822468

Locations: 🇺🇸
Southern Cancer Center PC, Mobile, Alabama, United States
🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 12 locations

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Phase 3

Active, not recruiting

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizumab (SEG101)
Drug: Placebo

First Posted Date: 2019-01-24

Last Posted Date: 2025-05-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 259

Registration Number: NCT03814746

Locations: 🇺🇸
Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Levine Cancer Insitute Carolinas Healthcare System, Charlotte, North Carolina, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy